Eucrates Biomedical Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
IPO Year: 2020
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
15-12G - Eucrates Biomedical Acquisition Corp. (0001822929) (Filer)
25-NSE - Eucrates Biomedical Acquisition Corp. (0001822929) (Subject)
10-K - Eucrates Biomedical Acquisition Corp. (0001822929) (Filer)
8-K - Eucrates Biomedical Acquisition Corp. (0001822929) (Filer)
8-K - Eucrates Biomedical Acquisition Corp. (0001822929) (Filer)
NT 10-K - Eucrates Biomedical Acquisition Corp. (0001822929) (Filer)
8-K - Eucrates Biomedical Acquisition Corp. (0001822929) (Filer)
10-Q - Eucrates Biomedical Acquisition Corp. (0001822929) (Filer)
8-K - Eucrates Biomedical Acquisition Corp. (0001822929) (Filer)
8-K - Eucrates Biomedical Acquisition Corp. (0001822929) (Filer)
This live feed shows all institutional transactions in real time.
SC 13G/A - Eucrates Biomedical Acquisition Corp. (0001822929) (Subject)
SC 13G - Eucrates Biomedical Acquisition Corp. (0001822929) (Subject)
SC 13G - Eucrates Biomedical Acquisition Corp. (0001822929) (Subject)
SC 13G/A - Eucrates Biomedical Acquisition Corp. (0001822929) (Subject)
SC 13G - Eucrates Biomedical Acquisition Corp. (0001822929) (Subject)
Fastest customizable press release news feed in the world
NEW YORK, April 11, 2023 /PRNewswire/ -- Eucrates Biomedical Acquisition Corp. (NASDAQ:EUCR) (the "Company") announced the following today: The Company anticipates that it will not be able to consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association.Accordingly, the Company intends to dissolve and liquidate in accordance with the provisions of its Amended and Restated Memorandum and Articles of Association.As part of that dissolution and liquidation, the Company will redeem all of the outstandi
NEW YORK, June 1, 2021 /PRNewswire/ -- Eucrates Biomedical Acquisition Corp. (NASDAQ:EUCR) (the "Company"), a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, today announced that it received a notice ("Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule") because the Company failed to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the "Form 10-Q") with the Securit